Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VICTOR ANKOMA-SEY

NPI
1144226515
CMS profile
142864
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$53,367.74

163 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VICTOR ANKOMA-SEY

NPI 1144226515 · CMS profile ID 142864

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144226515?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VICTOR ANKOMA-SEY, NPI 1144226515, CMS profile ID 142864. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144226515?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). VICTOR ANKOMA-SEY, NPI 1144226515, CMS profile ID 142864. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144226515?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
VICTOR ANKOMA-SEY, NPI 1144226515, CMS profile ID 142864, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144226515?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

163 matching records · $53,367.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 163 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 163.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.6809/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153692558 CMS
FUJIFILM Healthcare Americas Corporation $100.0009/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146125452 CMS
Gilead Sciences, Inc. $150.0009/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734551 CMS
Intercept Pharmaceuticals, Inc. $15.9109/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113644115 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $2.7209/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153571976 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.7509/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153731813 CMS
AstraZeneca Pharmaceuticals LP $24.3009/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110544011 CMS
ABBVIE INC. $4.6109/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228729 CMS
Gilead Sciences, Inc. $28.6209/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734549 CMS
ABBVIE INC. $16.0709/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228727 CMS
Madrigal Pharmaceuticals $9.4509/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144160381 CMS
ABBVIE INC. $129.4509/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228725 CMS
ABBVIE INC. $19.0009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228723 CMS
ABBVIE INC. $21.8509/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228721 CMS
Intercept Pharmaceuticals, Inc. $16.7709/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113644117 CMS
Gilead Sciences, Inc. $28.1908/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734547 CMS
Ipsen Biopharmaceuticals, Inc $25.3408/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091952892 CMS
Ipsen Biopharmaceuticals, Inc $24.4208/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091952894 CMS
Ipsen Biopharmaceuticals, Inc $22.6608/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091952888 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.5408/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153588918 CMS
Gilead Sciences, Inc. $25.5808/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734545 CMS
Gilead Sciences, Inc. $30.9808/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734543 CMS
Phathom Pharmaceuticals, Inc. $21.6908/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151035419 CMS
ABBVIE INC. $15.2908/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228719 CMS
Gilead Sciences, Inc. $32.6007/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734541 CMS
Intercept Pharmaceuticals, Inc. $540.0007/25/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113644119 CMS
Gilead Sciences, Inc. $128.3407/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734539 CMS
Mallinckrodt Hospital Products Inc. $29.2207/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145046871 CMS
Intercept Pharmaceuticals, Inc. $21.4107/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113644107 CMS
Gilead Sciences, Inc. $29.4707/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734537 CMS
ABBVIE INC. $23.3907/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228717 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.5807/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153591364 CMS
ABBVIE INC. $18.9707/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228715 CMS
FUJIFILM Healthcare Americas Corporation $74.3306/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146124518 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.4806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153510409 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.3606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153570520 CMS
ABBVIE INC. $14.5406/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228713 CMS
Gilead Sciences, Inc. $30.7606/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734535 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.0006/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153428469 CMS
CONMED Corporation $101.6606/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142396341 CMS
Intercept Pharmaceuticals, Inc. $15.7806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113644109 CMS
Gilead Sciences, Inc. $24.5706/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133734533 CMS
ABBVIE INC. $15.8805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228711 CMS
Phathom Pharmaceuticals, Inc. $20.6005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151035417 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.9005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153506129 CMS
ABBVIE INC. $22.7805/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228709 CMS
ABBVIE INC. $18.1005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228707 CMS
Ipsen Biopharmaceuticals, Inc $2,760.0005/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091952896 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.2105/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153576290 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $2.3705/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153620325 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $61,372.47 187
PY2020 $21,123.45 147
PY2021 $34,007.36 148
PY2022 $44,659.13 146
PY2023 $43,350.98 142
PY2024 $53,367.74 163
PY2025 $82,492.56 205

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $47,283.00 21
PY2024 Principal investigator $256,924.43 34
PY2023 Principal investigator $97,952.66 17
PY2022 Recipient $5,726.28 1
PY2022 Principal investigator $33,281.54 10
PY2021 Principal investigator $14,400.32 10
PY2020 Principal investigator $90,343.86 25
PY2019 Principal investigator $52,122.40 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $120.24 10/30/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252234
Principal investigator 1 Ipsen Bioscience Inc. $7,044.77 10/03/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545435
Principal investigator 1 Madrigal Pharmaceuticals $1,594.08 10/03/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251035
Principal investigator 1 Bausch Health US, LLC $1,239.30 09/17/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842494
Principal investigator 1 Bausch Health US, LLC $1,451.93 08/14/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842490
Principal investigator 1 Madrigal Pharmaceuticals $1,594.08 07/10/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246826
Principal investigator 1 Bausch Health US, LLC $1,513.89 06/11/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842513
Principal investigator 1 Ipsen Bioscience Inc. $2.01 06/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545433
Principal investigator 1 GlaxoSmithKline, LLC. $11,739.63 05/27/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165682
Principal investigator 1 Bausch Health US, LLC $425.25 05/13/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842505
Principal investigator 1 Ipsen Bioscience Inc. $6.70 05/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545431
Principal investigator 1 Madrigal Pharmaceuticals $10,216.94 04/15/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242361
Principal investigator 1 Bausch Health US, LLC $1,453.14 04/07/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842509
Principal investigator 1 Ipsen Bioscience Inc. $6.70 04/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545429
Principal investigator 1 Bausch Health US, LLC $1,931.85 03/11/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842498
Principal investigator 1 Ipsen Bioscience Inc. $6.70 03/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545427
Principal investigator 1 Ipsen Bioscience Inc. $4,997.90 02/06/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545423
Principal investigator 1 Ipsen Bioscience Inc. $6.70 02/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545425
Principal investigator 1 Bausch Health US, LLC $425.25 01/13/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842502
Principal investigator 1 Ipsen Bioscience Inc. $1,499.24 01/09/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545421
Principal investigator 1 Ipsen Bioscience Inc. $6.70 01/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545419